Seegene and Eisai's Eidia Partner on MDx Tests in Japan | GenomeWeb

Seegene and Eidia, the in vitro diagnostics subsidiary of Japanese pharmaceutical firm Eisai, have entered into a collaborative agreement to bring new multiplex molecular diagnostic tests to Japan.

Under the agreement, Eidia gains access to Seegene's portfolio of multiplexed molecular diagnostics tests based on the company's tagging oligonucleotide capture and extension, or TOCE, technology.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.